Asset 2 Conferences
Coyle Anthony - profile picture

Anthony Coyle

CEO, Pandion Therapeutics, US

Anthony “Tony” Coyle is Vice President and Chief Scientific Officer of the Centers for Therapeutic Innovation (CTI) based out of Boston. CTI was established in late 2010 as a new model to drive innovation in BioTherapeutics R & D. Tony is responsible for the CTI sites, which currently include CTI – New York City, CTI- Boston and CTI-California. Tony is supported by his leadership team, which will includes the site heads of each CTI, his operations team and project management. CTI is located in the CLS building at 3 blackfan circle, Boston MA at the Alexandria Centres at 1700 Owens St, San Francisco CA and 450 E 29th New York, NY

As a former Vice President and Global Head of Respiratory, Inflammation, and Autoimmunity Research at Medimmune Biologics, a Division of AstraZeneca, Tony has advanced a biologic portfolio from discovery to Phase Two in the areas of Respiratory and Autoimmune diseases including Lupus, Asthma and COPD.

Prior to joining Medimmune, Tony was Director of Research at Millennium Pharmaceuticals, where he led a group responsible for the identification of novel target genes as well as for late stage lead optimization and delivery of both small molecule and biologic development candidates.

Tony has been Associate Professor in the Department of Pathology and Experimental Therapeutics at McMaster University in Ontario since 1992, and has authored more than 200 manuscripts. Tony is a member of the Alliance for Lupus Research (ALR) Scientific Advisory Board as well as a Scientific Advisory member of the CTSA (C4) coordinating center. He holds a B.Sc. first class Honours and a Ph.D. from Kings College, University of London.